Join the Hypertrophic Cardiomyopathy group to help and get support from people like you.
Hypertrophic Cardiomyopathy News
Related terms: Cardiomyopathy, hypertrophic, HCM
U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
PRINCETON, N.J.-- April 17, 2025 – (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information...
MEK Inhibition Beneficial for Children With Subset of Severe Hypertrophic Cardiomyopathy
MONDAY, Jan. 13, 2025 – For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces...
AI-Enabled Stethoscope Boosts Diagnosis of Pregnancy-Related Cardiomyopathy
TUESDAY, Sept. 10, 2024 – In pregnant and postpartum women, artificial intelligence (AI)-guided screening using a digital stethoscope improves the diagnosis of pregnancy-related cardiomyopathy,...
FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules)...